Key details
Phase
Safety & dosing / Large-scale testing
Sponsor
Weiliang Shen, Ph.D., M.D.
Enrollment target
~20 participants
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
50 Years – 75 Years
Last updated January 2025